Comparative study of carbazochrome sodium sulfonate and tranexamic acid in reducing blood loss and inflammatory response following direct anterior total hip arthroplasty: a prospective randomized controlled trial
International Orthopaedics · 2023-10 · 47 (10) · 2553-2561
DOI: 10.1007/s00264-023-05853-3 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Orthopaedics, online erschienen am 20.06.2023. Verfasst von Shuwei Ye und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedics surgery, West China Hospital, Sichuan University, 37# Wainan Guoxue Road, Chengdu, 610041, China. Hauptthemen laut MEDLINE: Tranexamic Acid, Arthroplasty, Replacement, Hip, Antifibrinolytic Agents, Venous Thromboembolism. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: Carbazochrome sodium sulfonate (CSS) is a haemostatic agent. However, its hemostatic and anti-inflammatory effects in patients undergoing total hip arthroplasty (THA) via a direct anterior approach (DAA) are unknown. We investigated the efficacy and safety of CSS combined with tranexamic acid (TXA) in THA using DAA. METHODS: This study enrolled 100 patients who underwent primary, unilateral THA through a direct anterior approach. Patients were randomly divided into two groups: Group A used a combination of TXA and CSS, while Group B used TXA only. The primary outcome was total perioperative blood loss. The secondary outcomes were hidden blood loss, postoperative blood transfusion rate, inflammatory reactant levels, hip function, pain score, venous thromboembolism (VTE), and incidence of associated adverse reactions. RESULTS: The total blood loss (TBL) in group A was significantly lower than in group B. The levels of inflammatory reactants and the rate of blood transfusion were also significantly lower. However, the two groups had no significant differences in intraoperative blood loss, postoperative pain score, or joint function. There were no significant differences in VTE or postoperative complications between the groups. CONCLUSION: As a haemostatic agent, CSS combined with TXA can reduce postoperative blood loss in patients undergoing THA via DAA and seems to have an anti-inflammatory effect. Moreover, it did not increase the incidence of VTE or its related complications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopaedics surgery, West China Hospital, Sichuan University, 37# Wainan Guoxue Road, Chengdu, 610041, China.
- Animal Experimental Center, West China Hospital, Sichuan University, 37# Wainan Guoxue Road, Chengdu, 610041, China.
- Department of Orthopaedics surgery, West China Hospital, Sichuan University, 37# Wainan Guoxue Road, Chengdu, 610041, China. kangpengde69@126.com.
Zitieren
APA
Ye, S., Chen, M., Luo, Y., Zhao, C., Li, Q., & Kang, P. (2023). Comparative study of carbazochrome sodium sulfonate and tranexamic acid in reducing blood loss and inflammatory response following direct anterior total hip arthroplasty: a prospective randomized controlled trial. International Orthopaedics, 47(10), 2553-2561. https://doi.org/10.1007/s00264-023-05853-3
Vancouver
Ye S, Chen M, Luo Y, Zhao C, Li Q, Kang P. Comparative study of carbazochrome sodium sulfonate and tranexamic acid in reducing blood loss and inflammatory response following direct anterior total hip arthroplasty: a prospective randomized controlled trial. International Orthopaedics. 2023;47(10):2553-2561. doi:10.1007/s00264-023-05853-3
BibTeX
@article{Ye2023,
author = {Ye, Shuwei and Chen, Maojia and Luo, Yue and Zhao, Chengcheng and Li, Qianhao and Kang, Pengde},
title = {Comparative study of carbazochrome sodium sulfonate and tranexamic acid in reducing blood loss and inflammatory response following direct anterior total hip arthroplasty: a prospective randomized controlled trial},
journal = {International Orthopaedics},
year = {2023},
volume = {47},
number = {10},
pages = {2553--2561},
doi = {10.1007/s00264-023-05853-3}
}
EUVIMED